For years, our personal data has been traded, tracked and monetised by tech companies \u2013 basic things like clicks, locations, heart rates and even our sleeping patterns. But now, we\u2019re entering a far more intimate frontier: the commoditisation of biology itself.<\/p>\n
But, in 2025, the lines between health, data and commerce are blurring faster than ever. DNA testing kits, biometric wearables<\/a> and AI-driven wellness platforms are unlocking unprecedented insights about our bodies. However, beneath the promise of personalised health lies a bit of a disconcerting question \u2013 who actually owns your genetic data? You, or the company that analyses it?<\/p>\n And moreover, if we don\u2019t yet have a confident answer to that question (or simply if the answer isn\u2019t \u201cyou\u201d), perhaps we should take a beat before diving into DNA testing head first.<\/p>\n \u00a0<\/p>\n The Rise of the Genetic Data Economy<\/strong><\/p>\n \u00a0<\/p>\n Once the domain of research labs and ancestry enthusiasts, DNA analysis is now a consumer product. Companies like 23andMe and AncestryDNA, for instance, popularised at-home testing kits that can trace family heritage or reveal predispositions to disease. Millions have eagerly shared their genetic material, lured by curiosity and convenience. After all, the idea of being able to find out so much about yourself, your ancestry and your family is an incredible thought.<\/p>\n But, few realise that this information is often stored, analysed and sometimes licensed for profit. 23andMe, for instance, entered a $300 million partnership with GlaxoSmithKline in 2018, giving the pharmaceutical giant access to anonymised genetic data<\/a> to aid in drug development. While this collaboration is framed as a win for medical innovation, it also highlights the commercial potential of DNA as a data source. It also raises questions about exactly what \u201canonymous\u201d really means in this context \u2013 how anonymous is anonymous?<\/p>\n Indeed, genetic information has become a kind of biological currency \u2013 highly valuable to researchers, insurers and AI-driven health startups. Yet, most consumers don\u2019t fully understand what they\u2019ve agreed to when they tick \u201cI accept\u201d on a company\u2019s privacy policy, and we\u2019re now realising just how problematic this could be.<\/p>\n \u00a0<\/p>\n The Legal Grey Zone of Genetic Ownership<\/strong><\/p>\n \u00a0<\/p>\n So, who owns your DNA once it\u2019s been digitised? The answer isn\u2019t simple, and that\u2019s kind of the problem.<\/p>\n In the UK and EU, data protection laws like GDPR classify genetic data as \u201cspecial category data\u201d, meaning it requires extra safeguards. However, they stop short of explicitly defining ownership. Once you\u2019ve submitted a sample, companies often claim broad rights to use or store that information, sometimes indefinitely.<\/p>\n In the US, where data privacy laws are patchier, most genetic testing firms maintain that you still \u201cown\u201d your DNA, but their terms of service often grant them a perpetual, global licence to analyse, share or sell anonymised versions of it.<\/p>\n The result is a murky landscape where consumers retain theoretical ownership but very little control. You may \u201cown\u201d your genetic data, but the company owns the systems, the algorithms and the datasets that give that data meaning. And the problem is that whenever regulations surrounding these sorts of things are even just a little murky, it leaves room for some questionable activity.<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n The Wearable Revolution Meets Biometric Reality<\/strong><\/p>\n \u00a0<\/p>\n If genetic testing was the first phase of the personal biology boom, biometric wearables are the next.<\/p>\n Devices like Whoop, Oura<\/a> and even the Apple Watch are evolving from step counters into continuous health monitors. Some are already exploring blood biomarkers and metabolic data \u2013 the kind of physiological information once only available through lab tests.<\/p>\n These innovations promise huge potential for early disease detection and personalised healthcare. Yet, they also expand the volume of sensitive biological data being collected \u2013 and often stored in the cloud.<\/p>\n The more integrated these devices become, the blurrier the distinction between medical data and consumer data. A smartwatch that monitors blood oxygen might sound harmless, until that data is used to predict long-term health risks. Imagine a future where a health insurer adjusts your premium based on your resting heart rate trends or an employer infers fatigue or stress from your wearable data?<\/p>\n It\u2019s not far-fetched. In fact, startups in the UAE and the US are already experimenting with bio-insurance models that link premiums to lifestyle metrics. And to say that\u2019s controversial would be a massive understatement.<\/p>\n \u00a0<\/p>\n The Potential for Misuse<\/strong><\/p>\n \u00a0<\/p>\n The greatest concern around DNA and biometric data isn\u2019t necessarily corporate greed, it\u2019s about misuse.<\/p>\n Genetic databases have already been used by law enforcement agencies in the US to solve cold cases through \u201cgenetic genealogy\u201d \u2013 a move that reignited debates around privacy and consent. Meanwhile, cybersecurity experts warn that hacked DNA databases could expose not only your identity but your relatives\u2019 health information.<\/p>\n There\u2019s also the matter of bias and discrimination. Studies show that genetic algorithms and facial recognition systems alike tend to perform better for some demographics than others. If such data begins informing medical research or insurance models, inequality could be baked into the biology of the system itself.<\/p>\n And, once your genetic data is leaked, there\u2019s no way to change it. Unlike a password, your DNA can\u2019t be reset.<\/p>\n There\u2019s no going back. So, surely that means that now is the time to think twice before sharing?<\/p>\n \u00a0<\/p>\n